This includes eligibility screening, dose titration, a critical phase in tirzepatide therapy where doses advance from the 2.5 mg starting dose through escalating levels (5 mg, 7.5 mg, 10 mg, and 12.5 mg or 15 mg), and ongoing monitoring of metabolic and clinical outcomes
These medications appear to reduce the production of pro-inflammatory cytokinessignalling molecules that drive inflammationsuch as tumour necrosis factor-alpha (TNF-), interleukin-6 (IL-6), and interleukin-1 beta (IL-1)
The appeal of GLP-1 weight loss treatments, such as Semaglutide and Tirzepatide, lies in their ability to provide significant results without the intense restrictions often associated with diets or the grueling routines required by exercise-only programs
GLP-1RAs can suppress local inflammation caused by agonistic anti-CD3 antibody through intraepithelial lymphocytes (IELs) (Wong et al., 2022)